• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Aduro BioTech

edit

Aduro BioTech, Inc., a development stage biopharmaceutical company, engages in the development of early stage cancer therapies. The company focuses on the development of its minimally invasive NT and TNT cancer treatment systems, which use iron oxide nano-particles that generate heat when exposed to an externally applied magnetic field and kills tumor cells without the toxicity or collateral damage. It offers therapies for breast, prostate, colorectal, lung, pancreas, ovarian, and head and neck cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Recent Milestones

edit

• 
  Aduro BioTech received $6.5M in Private Equity funding. (1/31/13)
  Posted 1/31/13 at 8:37pm via finsmes.com
• 
  Aduro BioTech received $19.3M in Series B funding. (4/20/11)
  Posted 4/20/11 at 5:35pm via businesswire.com
• 
  Aduro BioTech added Stephen T. Isaacs as Chairman and CEO.
  Posted 4/20/11 at 5:35pm
• 
  Aduro BioTech added Seth David Model as acting CFO.
  Posted 4/20/11 at 5:35pm

Videos

Screenshots

edit

Sources

1. Aduro BioTech Completes $19.25 Million Series B Financing (businesswire.com) [edit]
2. Aduro BioTech Closes $6.5M Equity Financing (finsmes.com) [edit]